FDA Greenlights Daiichi Sankyo’s Blood Cancer Drug, A Promising Competitor to Novartis’ Rydapt
The FDA has approved Daiichi Sankyo's (OTC: DSNKY) Vanflyta (quizartinib) in
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
All news is property of their respective owners.
